Document is current
Any future updates will be listed below
-
Authors
Lau, Tang Ching
Chang, Dong-Gune
Chen, Chung-Hwan
Huang, Shuang
Lau, Edith M. C.
Law, Sheung-Wai
Lee, Young-Kyun
Tolman, Cae
Canals, Laura
Yeo, See-Hwee
Yu, Jing
Ebeling, Peter R.
-
Funding
Funding for this research was provided by:
Amgen
- License Information
-
More Information
Article History
Received: 9 June 2025
Accepted: 15 October 2025
First Online: 19 November 2025
Declarations
:
: Shuang Huang, Cae Tolman, Laura Canals are employees and stockholders of Amgen Inc. See-Hwee Yeo and Jing Yu are employees of Real World Solutions, IQVIA Solutions Asia. Peter R. Ebeling received research funding and honoraria from Amgen. Other authors report no other potential conflicts of interest. The study medications (denosumab and alendronate) were not reimbursed by Sponsor (Amgen) or IQVIA.
: The study protocol received ethical approval from the Institutional Review Board of all local sites (Supplementary Table 6).
: All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.
